• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Clear Street Launches Healthcare & Biotechnology Equity Research

    12/17/24 2:00:00 PM ET
    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $CGEM alert in real time by email

    Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises

    Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives products and markets.

    Ed Tilly, President and CEO-Elect of Clear Street said, "The launch of our Healthcare Equity Research franchise demonstrates our commitment to providing capabilities that align with our clients' evolving needs. Our expanded equity research service complements our full suite of existing products and allows us to continue providing institutional clients the tools, teams and capabilities they need to navigate global markets and execute successful investment strategies."

    Led by Director of Research Mara Goldstein, the new Healthcare Research franchise provides in-depth market analysis and investment insights to the firm's expanding institutional client base. To launch coverage, Clear Street has appointed Kaveri Pohlman, Ph.D. and William "Bill" Maughan, Ph.D. as Managing Directors and Senior Equity Analysts, reporting to Ms. Goldstein.

    "Fueled by scientific advancements across all fields of medicine, the healthcare sector, particularly biotechnology, has grown immensely and has become a fundamentally important sector of the economy for investors," said Ms. Goldstein. "As the number of biotechnology companies continues to grow, we think it's important to be a voice in the space, analyzing and highlighting under-followed and under-represented companies that our clients, such as specialist hedge funds and dedicated healthcare fund investors care about."

    Dr. Kaveri Pohlman's research coverage will initially focus on oncology and autoimmune disease (I&I), spanning multiple technologies, from cell to gene therapy. Prior to joining Clear Street, Dr. Pohlman was a Senior Analyst at BTIG where she covered large and small-cap biotechnology companies. Dr. Pohlman earned a Ph.D. in molecular and cellular biology from SUNY Downstate Medical Center, an MS in biotechnology from New York University's Tandon School of Engineering and an MBA from Birla Institute of Management Technology.

    Dr. Bill Maughan brings deep experience in Equity Research across several therapeutic areas, and will continue to do so at Clear Street, including oncology, ophthalmology and genetic medicine, including RNA technologies. Prior to joining Clear Street, Dr. Maughan was a Senior Biotechnology Analyst with Canaccord Genuity, focusing on solid tumor oncology. Dr. Maughan earned a Ph.D. in Biochemistry, Cell and Molecular Biology at the Weill Cornell Graduate School of Medical Sciences and a bachelor's degree in Biological Sciences from Fordham University.

    Specific coverage launch includes:

    Healthcare: Biotechnology

    • Cargo Therapeutics (NASDAQ:CRGX)
    • Century Therapeutics (NASDAQ:IPSC)
    • Cullinan Therapeutics (NASDAQ:CGEM)
    • Delcath Systems (NASDAQ:DCTH)
    • Enliven Therapeutics (NASDAQ:ELVN)
    • Erasca (NASDAQ:ERAS)
    • Immatics (NASDAQ:IMTX)
    • Janux Therapeutics (NASDAQ:JANX)
    • MoonLake Immunotherapeutics (NASDAQ:MLTX)
    • Nuvation Bio (NYSE:NUVB)
    • Protagonist Therapeutics (NASDAQ:PTGX)
    • YmAbs Therapeutics (NASDAQ:YMAB)

    The launch of Healthcare Equity Research enhances Clear Street's growing research franchise and complements the Company's already existing product offerings across prime brokerage, professional clearing, futures trading and investment banking services. The expanding Equity Research offering demonstrates Clear Street's commitment to areas where institutional clients are actively seeking specialized insights. The Company also recently launched Clear Street UK, a pivotal step in building a global, full-service institutional business powered by cloud-based, financial technology.

    About Clear Street:

    Clear Street is modernizing the brokerage ecosystem with financial technology and services that empower market participants with real-time data and best-in-class products, tools and teams, to navigate capital markets around the world. Complemented by white-glove service, Clear Street's cloud-native, proprietary product suite delivers financing, derivatives, execution and more to power client success, adding efficiency to the market and enabling clients to minimize risk, redundancy and cost. Clear Street's goal is to create a single platform for every asset class, in every country and in any currency. For more information, visit https://clearstreet.io.

    Clear Street does not provide investment, legal, regulatory, tax, or compliance advice. Consult professionals in these fields to address your specific circumstances. These materials are: (i) solely an overview of Clear Street's products and services; (ii) provided for informational purposes only; and (iii) subject to change without notice or obligation to replace any information contained therein.

    Products and services are offered by Clear Street LLC as a Broker Dealer member FINRA and SIPC and a Futures Commission Merchant registered with the CFTC and member of NFA. Additional information about Clear Street is available on FINRA BrokerCheck, including its Customer Relationship Summary and NFA BASIC | NFA (futures.org).

    Copyright © 2024 Clear Street LLC. All rights reserved. Clear Street and the Shield Logo are Registered Trademarks of Clear Street LLC

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241217931998/en/

    Get the next $CGEM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CGEM
    $CRGX
    $DCTH
    $ELVN

    CompanyDatePrice TargetRatingAnalyst
    Protagonist Therapeutics Inc.
    $PTGX
    6/17/2025$72.00Buy
    Citigroup
    Enliven Therapeutics Inc.
    $ELVN
    6/16/2025$37.00Buy
    Goldman
    Cullinan Therapeutics Inc.
    $CGEM
    6/11/2025$22.00Buy
    Stifel
    Immatics N.V.
    $IMTX
    5/28/2025$10.00Buy
    Deutsche Bank
    MoonLake Immunotherapeutics
    $MLTX
    5/19/2025$61.00Peer Perform → Outperform
    Wolfe Research
    Nuvation Bio Inc.
    $NUVB
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    Y-mAbs Therapeutics Inc.
    $YMAB
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    Erasca Inc.
    $ERAS
    3/26/2025$5.00Outperform
    Raymond James
    More analyst ratings

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    SEC Filings

    See more
    • SEC Form 144 filed by MoonLake Immunotherapeutics

      144 - MoonLake Immunotherapeutics (0001821586) (Subject)

      7/3/25 1:23:21 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Erasca, Inc. (0001761918) (Filer)

      6/26/25 5:04:51 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)

      6/26/25 4:08:54 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

      6/30/25 11:02:00 AM ET
      $ARAY
      $CLRB
      $ERAS
      $INTS
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

      Guidelines include the next-generation targeted therapy with Preferred status across all lines of therapy in advanced setting, including patients with brain metastases and acquired resistance mutations Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI™) has been added as a Preferred Agent in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Non-Small Cell Lung Cancers (NSCLC), updated on June 20. Specifically, the NCCN Guidelines® now include taletrectinib (IBTROZI) as a Preferred Agent for both first-li

      6/24/25 7:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

      BOULDER, Colo., June 16, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant, which represent

      6/16/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Financials

    Live finance-specific insights

    See more
    • Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

      Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 90 patients enrolled and a median treatment duration of ~29 weeks at cutoff Enliven will host a webcast and conference call today, June 13, at 1:30 p.m. ET BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutic

      6/13/25 6:02:00 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

      Approval follows Priority Review and is supported by the robust TRUST clinical program, in which IBTROZI treatment demonstrated high, durable response rates and brain-penetrant efficacy across different lines of therapy The safety and tolerability of IBTROZI have been well established in the pivotal program, with one of the largest safety datasets in ROS1+ NSCLC showing a favorable and consistent profile Company to host conference call tomorrow, June 12 at 7:30 a.m. EDT Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (

      6/11/25 1:20:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

      Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of diseases while maintaining cash runway into 2028 Company to host conference call today at 4:30 pm ET CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into an agreement with Genrix Bio for a global (ex-Greater China), all indication, exclusive license to velinotamig,

      6/4/25 4:02:00 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Protagonist Therapeutics with a new price target

      Citigroup initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $72.00

      6/17/25 7:50:36 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Enliven Therapeutics with a new price target

      Goldman initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

      6/16/25 7:46:51 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel resumed coverage on Cullinan Therapeutics with a new price target

      Stifel resumed coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $22.00

      6/11/25 8:09:08 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Radhakrishnan Anup sold $6,822 worth of shares (1,632 units at $4.18), decreasing direct ownership by 1% to 120,781 units (SEC Form 4)

      4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)

      7/3/25 6:57:37 PM ET
      $CRGX
    • Director Tyagi Ashu was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      7/2/25 4:20:24 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hamill Laura was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

      4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

      7/2/25 4:20:27 PM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      10/2/24 4:43:10 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

      5/23/24 10:32:08 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

      Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

      3/21/24 10:20:07 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:15 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF PEOPLE OFFICER Markel Stacy bought $17,100 worth of shares (10,000 units at $1.71), increasing direct ownership by 51% to 29,591 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:21 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Sauvage Philippe bought $13,216 worth of shares (7,300 units at $1.81), increasing direct ownership by 281% to 9,902 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:19 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Century Therapeutics Inc.

      SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

      11/27/24 6:51:58 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/15/24 10:33:51 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 9:46:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

      6/30/25 11:02:00 AM ET
      $ARAY
      $CLRB
      $ERAS
      $INTS
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

      Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J

      5/15/25 8:00:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Beta Bionics Announces Board Appointment of Gerard Michel

      IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

      3/27/25 4:45:06 PM ET
      $BBNX
      $DCTH
      Medical/Dental Instruments
      Health Care